News

As the number of metabolic components increased, so did the risk of adverse outcomes in patients with biopsy-proven IgAN.

Submission of the supplemental NDA was based on positive findings from the FINEARTS-HF trial investigating finerenone for heart failure with an LVEF ≥40%.

4D-150 shows promising efficacy and safety in DME as FDA greenlights Phase 3 trial for Biologics License Application submission.

This analysis highlights the transcriptomic patterns of chronic hand eczema, indicating the potential of novel drug targets.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

New research reveals that frequent social media use, especially active use of platforms such as TikTok and Facebook, is linked to greater irritability levels.

Non-Hispanic Black and Hispanic children were less likely to undergo preemptive KT and had longer wait times than non-Hispanic White children.

These findings highlight the value in understanding and recognizing gender differences in patient experiences with hidradenitis suppurativa and their impact on life quality.

A recent study showed expression profiles of amacrine cells, the interneurons within the retina, were enriched in schizophrenia genetic risk factors.

Aflibercept 8 mg achieves non-inferior vision gains with an every 8-week dosing interval in patients with macular edema following retina vein occlusion.

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

New topline data released by Inmagene indicate positive findings from a phase 2a trial on IMG-007 for moderate-to-severe atopic dermatitis.

Additional TEASE-3 participants who completed 24 months of gildeuretinol therapy reported no progression in Stargardt disease, including stable visual acuity.

In this analysis, investigators highlighted various disease-related views and experiences dermatologists may wish to consider among Latine patients with psoriasis.

After accepting the avacincaptad pegol sNDA on January 6, 2025, the FDA has set a target action date for February 26.

Individuals with stable schizophrenia struggle to recognize facial emotions such as sadness, disgust, and anger—but not happiness—which may impact social interactions.

Findings from the HOPE Consortium Trial suggest PCST can help pain interference and quality of life in patients on hemodialysis experiencing chronic pain.

Study findings highlight increasing rates of AH among adolescents and younger adults, with women facing worse long-term liver-related outcomes.

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

Patients in this post-hoc analysis with elevated CRP were found to have a higher BMI and more severe hidradenitis suppurativa.

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in ALD and MASLD.

The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.

The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting

This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.

The month in review features coverage of renal pipeline updates, a new nephrology podcast episode, and recent research in IgAN and FSGS.